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Available online 5 March 2011Substance P (SP) is a neuropeptide that can modulate inflammatory mediator release
through activation of NK1 receptors (NK1R). Some studies have also suggested the
involvement of SP in lipopolysaccharide (LPS)-induced fever. However, the precise
contribution of this neuropeptide to the pathways activated during fever is unknown. In
this studywe investigated the effect of a selective NK1R antagonist, SR140333B, on the febrile
response induced by LPS and cytokines. Our results show that the systemic injection of
SR140333B did not modify the fever induced by LPS at a dose that is able to reduce protein
extravasation induced by SP in the skin. On the other hand, intracerebroventricular
administration of SR140333B significantly reduced the fever induced by peripheral
injection of LPS. These data emphasize an important role for SP in the central nervous
system during the febrile response to LPS, and are reinforced by the fact that
intracerebroventricular injection of SP also induced fever in a dose-dependent manner in
captopril-treated rats. Considering that the febrile response can result from the generation of
several endogenous pyrogens, among them interleukin (IL)-1β and macrophage
inflammatory protein-1α (CCL3/MIP-1α), we also examined the effect of SR140333B on the
fever induced by these cytokines which act through prostaglandin-dependent and -
independent mechanisms, respectively. Surprisingly, SR140333B did not modify the febrile
response to IL-1β or CCL3/MIP-1α. Altogether these data suggest that the central action of SP
is essential for LPS-, but not for IL-1β- or CCL3/MIP-1α-induced fever.
© 2011 Elsevier B.V. Open access under the Elsevier OA license.Keywords:
Fever
Lipopolysaccharide
Substance P
SR140333B
Interleukin-1β
Macrophage inflammatory protein-1α1. Introduction
The febrile response is a key phenomenon of the acute phase
reaction, which is also characterized by changes in several
physiological parameters such as the levels of liver proteins,
hormones and cells in blood, sleep phases, food intake, andFarmacologia, Setor de C
l. Fax: +55 41 3266 2042.
Zampronio).
the Elsevier OA license.others (Zeisberger, 1999). Due to the increased body temper-
ature, defense mechanisms are stimulated, making the febrile
response relevant to protection of the body's integrity against
invading organisms (Blatteis and Sehic, 1998). The main brain
area involved in the control of the body temperature is the
anterior hypothalamic pre-optic area (POA), which transducesiências Biológicas, Universidade Federal do Paraná, Caixa Postal
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temperature set point, resulting in fever (Blatteis and Sehic,
1998; Zeisberger, 1999).
The systemic administration of LPS to experimental
animals represents one of the classical models of fever
induction since it reproduces what naturally occurs during
inflammatory and infectious processes. LPS stimulatesmacro-
phages,monocytes, and other cells to release cytokines, which
can act as endogenous pyrogens to promote fever (Roth and
De Souza, 2001). Interleukin (IL)-1β was the first-described
endogenous pyrogen (Dinarello, 1984) and despite the subse-
quent identification of others it probably remains the most
studied (Helle et al., 1988; Watanabe, 1992; Zampronio et al.,
1994). A number of mechanisms have been suggested to
explain how the peripherally produced endogenous pyrogens
exert their effects on the central nervous system (CNS) to
produce fever (Banks et al., 1991; Banks et al., 1994; Cao et al.,
1996; Konsman et al., 2004), but it is clear that the synthesis
and release of central mediators is required to bring about the
necessary changes in the hypothalamic set point. Several
central mediators have been proposed including prosta-
glandins E2 (PGE2) and F2α (PGF2α) (Coelho et al., 1993; Milton,
1989), corticotrophin releasing factor (CRF) (Rothwell, 1989;
Zampronio et al., 2000), endothelin-1 (ET-1) (Fabricio et al.,
1998), endogenous opioids (Benamar et al., 2000; Fraga et al.,
2008), endocannabinoids (Fraga et al., 2009) and also substance
P (SP) (Blatteis et al., 1994). Among these, prostaglandins
derived from both peripheral and central sources appear to be
important (Ivanov et al., 2003; Steiner et al., 2006). The febrile
response is triggered by the action of PGE2 on POA neurons
mainly through the EP3 receptor (EP3R) (Lazarus et al., 2007;
Oka et al., 2003) which would relief the tonic inhibition that
these neurons exert over the dorsomedial hypothalamus to
activate brown adipose tissue thermogenesis and over the
rostral raphe pallidus to elicit cutaneous vasoconstriction
(Nakamura et al., 2005; Rathner et al., 2008; Yoshida et al.,
2009) probably through two separate pathways (Nakamura
et al., 2009; Ootsuka and McAllen, 2006).
Nonetheless, how the other centralmediators interact with
these neurons in the hypothalamus to produce fever is less
known. There is also the possibility that different central
mediators are involved in different pathways for fever
induction. For example, endogenous opioids are involved in
the febrile response induced by LPS and several cytokines but
not by IL-1β (Fraga et al., 2008), while ET-1 is involved in the
febrile response induced only by LPS and pre-formed pyro-
genic factor (Fabricio et al., 2006), but not in the fever induced
by other cytokines. Meanwhile, both endogenous opioids and
ET-1 induce fever by prostaglandin-independent mechanisms
(Fabricio et al., 2005; Fraga et al., 2008).
Although substance Pmay be involved inmediating certain
febrile responses, its actions are not well understood. Sub-
stance P (SP: Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gli-Leu-Met-
NH2) is found in primary afferent fibers [A-δ, C and capsaicin-
sensitive fibers (Cahill and Coderre, 2002)] aswell as in the CNS
(Hurd et al., 1999), and there are several studies showing its
participation in inflammatory processes and, to a lesser
extent, in the febrile response. In the CNS, SP is present in
several structures, including the POA [for review see (Otsuka
and Yoshioka, 1993)]. Although the main source of SP isneuronal cells, some studies with rodents have shown that SP
can also be synthesized by macrophages, eosinophils, lym-
phocytes, dendritic cells, and others (Bost, 2004; Ho et al., 1997;
Satake and Kawada, 2006). SP effects are mediated almost
exclusively by the metabotropic NK1R, which is expressed in
several structures of the CNS, including the putamen, caudate
nucleus and hypothalamus, and in the peripheral nervous
system, where it is found in dorsal root ganglia and intestinal
intrinsic neurons [for review see (Harrison and Geppetti, 2001;
Tuluc et al., 2009)]. Furthermore, the NK1R can also be
expressed by immune cells such asmacrophages, neutrophils,
lymphocytes and mast cells (Cooke et al., 1998; Ho et al., 1997;
Lai et al., 1998; Lambrecht et al., 1999).
The administration of NK1R antagonists reduced neutro-
phil migration induced by P. nigriventer venom (Costa et al.,
2002) or formalin (Santos et al., 2004), when systemically
injected, and reduced the febrile response to LPS when
administered centrally (Balasko et al., 2000; Szelenyi et al.,
1997) in laboratory animals, highlighting the participation of
SP in these events. In addition, some in vitro experiments have
shown that SP induces pro-inflammatory cytokine release
from rodent macrophages and granulocytes (Delgado et al.,
2003; Yaraee et al., 2003), which is crucial to the development
of the inflammatory and febrile responses and enhances
the release of pro-inflammatory cytokines in response to LPS
(Berman et al., 1996). Moreover, LPS itself can increase the
NK1R expression in some of these cells (Bost, 2004).
In view of such considerations, the present study aimed
to investigate, using a selective non-peptide NK1R antagonist
SR140333B, whether substance P, released in the periphery
or the CNS, participates in the febrile response induced by
LPS and two endogenous pyrogens: IL-1β, which induces a
prostaglandin-dependent fever, and CCL3/MIP-1α, which
induces a prostaglandin-independent fever in conscious rats.
In addition, we assessed the effects of centrally administered
substance P on body temperature in this species.2. Results
2.1. Peripheral injection of SR140333
Control animals treated only with vehicle or SR140333B
showed a small increase in body temperature over baseline
values, returning to pre-injection temperature after 1 h and
remaining at this level up to 6 h after administration. In sharp
contrast, those given LPS (30 μg/kg, i.p.) displayed an increase
in body temperature that peaked after around 2.5 h and
continued elevated for the remainder of the observation
period. Prior injection of the NK1R antagonist SR140333B
(0.3 mg/kg, data not shown or 1 mg/kg, i.p.) failed to impede
the development of LPS-induced fever (Fig. 1A and B). A higher
dose of SR140333B (3 mg/kg, i.p.) was tested but, in combina-
tion with LPS, this dose induced a significant decrease in body
temperature between 0 and 1.5 h (around 0.7 °C) after injec-
tion, which made the interpretation of the results difficult
(data not shown). SR140333B (1 mg/kg, i.p.) alone did not alter
body temperature from baseline (Fig. 1C). To verify if this dose
of SR140333B blocked the peripheral actions of SP we
Fig. 1 – Effect of peripheral treatment with NK1 receptor antagonist SR140333B on fever induced by LPS and protein
extravasation induced by SP in rats. SR140333B (SR, 1 mg/kg) or vehicle (Veh, Tween 80 1% in saline, 2 ml/kg) was given i.p.,
30 min before the i.p. injection of LPS (30 μg/kg) or saline (Sal) (panels A and B) or intradermal injection of SP (40 ng) or Sal (panel
D). Panel C shows the effect of SR or Veh on body temperature. Values represent themeans±S.E.M of the body temperature (°C),
fever index ( AUC in arbitrary units) or Evans blue content (μg) of 5–7 animals. *P<0.05 when compared to corresponding value
of Veh+Sal group. **P<0.05 when compared with Veh+SP-treated group.
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tion. Intradermal injection of SP induced a significant increase
in Evans blue extravasation when compared to saline in
vehicle-treated animals (Fig. 1D). As expected, the treatment
of the animals with SR140333B, at the same dose that did not
affect the febrile response, significantly reduced the protein
extravasation by 81% (Fig. 1D).
2.2. Central injection of SR140333B
In the next set of experiments we injected SR140333B or the
vehicle into the lateral ventricle of the animals. Control
animals treated only with the vehicle or SR140333B showed
much smaller changes in body temperature than in the
previous set of experiments. The pre-treatment of the animals
with SR140333B effectively reduced the febrile response
induced by LPS (Fig. 2). Fig. 2A shows the time-course of the
reduction in the febrile response induced by the higher dose
of SR140333B (3 μg, i.c.v.). This dose of SR140333B reduced
the fever index by 85% (Fig. 2B). A lower dose of SR140333B(1 μg, i.c.v.) also significantly reduced the febrile response
(a reduction of 50% in the fever index) to LPS while SR140333B
at 0.3 μg (i.c.v.) did not significantly change this response
(Fig. 2B). No changes in body temperature were seen in
animals which received the higher dose of SR140333B or
vehicle alone (Fig. 2C).
2.3. Febrile response induced by SP
In our attempts to induce a febrile response through the i.c.v.
injection of SP we tested different doses ranging from 15 to
1000 ng of SP. The responses, however, were not consistent
since only a few animals showed an increase in body
temperature when injected with SP (from 200 ng up to
1000 ng, data not shown). We then treated the animals with
captopril 5 μg, i.c.v. 30 min before any injection. The injection
of 250 ng of SP did not modify the body temperature of
animals; however, the injection of SP (500 or 750 ng, i.c.v., 2 μl)
in captopril-treated animals induced a febrile response which
started around 2 h after injection and persisted until the end
Fig. 2 – Effect of intracerebroventricular treatment with NK1
receptor antagonist SR140333B on fever induced by LPS in
rats. SR140333B (SR, 3, 1 and 0.3 μg) or vehicle (Veh, Tween
80 0.3% in saline, 2 μl) was given i.c.v., 30 min before the i.p.
injection of LPS (30 μg/kg) or saline (Sal) (panels A and B).
Panel C shows the effect of SR or Veh on body temperature.
Values represent the means±S.E.M of the body temperature
(°C) or fever index (AUC in arbitrary units) of 5–8 animals.
*P<0.05 when compared to corresponding value of Veh+Sal
group. **P<0.05 when compared with Veh+LPS-treated
group.
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with SR140333B, at the same dose that reduced the febrile
response to LPS (3 μg, i.c.v.), also completely blocked the febrile
response to SP (500 ng, i.c.v., Fig. 3B). Since no difference was
found between the 500 ng SP-treated group and the vehicle
plus 500 ng SP-treated group, these data were combined in
Fig. 3C.
2.4. Febrile response induced by IL-1β and CCL3/MIP-1α
Intracerebroventricular injection of IL-1β (3.12 ng, i.c.v.) clearly
induced a significant febrile response that started around 1 h
after injection and persisted until 6 h. Surprisingly, the treat-
ment of the animals with SR140333B (3 μg) did not change this
response (Fig. 4A and B). CCL3/MIP-1α (500 pg) also induced a
febrile response that started around 3 h and lasted up to 6 h.
Similarly, SR140333B was not able to reduce the febrile
response induced by this cytokine (Fig. 4C and D).3. Discussion
The data reported here show that the febrile response induced
by LPS in rats is dependent on the activation of central, but not
peripheral, NK1R. On the other hand, NK1R antagonist
treatment (i.p. or i.c.v.) did not affect basal body temperature,
suggesting that this peptide is not involved in thermoregula-
tory mechanisms under normal conditions. Meanwhile, our
other findings show that substance P is not involved in the
febrile response induced by IL-1β or CCL3/MIP-1α.
The NK1R antagonist used here was particularly interesting
for the investigation of the peripheral action of SP since there
is evidence that this antagonist does not cross the blood–brain
barrier (Jung et al., 1994). We found that the intraperitoneal
administration of SR140333B at a dose of 1.0 mg/kg was not
able to reduce LPS-induced fever. To be sure that this dose was
sufficient to reduce SP peripheral effects, we tested the effect
of this treatment on plasma extravasation induced by SP. This
event is caused by SP directly activating NK1R on endothelial
cells (Bowden et al., 1994) or through the release of other
mediators (Harrison and Geppetti, 2001; Maggi, 1997). Indeed,
peripherally administered SR140333B reduced the plasma
extravasation caused by SP by about 81%, indicating that this
antagonist is effective when administered peripherally and
confirming that the peripheral release of SP to act on NK1R is
not relevant to the febrile response induced by LPS.
However, it has been shown by others that SP does
participate in LPS-induced fever (Blatteis et al., 1994; Szelenyi
et al., 1997). These studies already indicated that centrally
released SP could be important for the febrile response using
other antagonists. Indeed, there is evidence for the particu-
larly high expression of SP receptors in the rat hypothalamus,
a region critically involved in temperature control and fever
responses (Tsuchida et al., 1990). Also, there is evidence for the
presence of SP and its precursor preprotachykinin A in the
hypothalamus of primates and rats (Gautreau and Kerdelhue,
1998; Hurd et al., 1999). Therefore, all the functional require-
ments for the local formation, release and action of SP appear
to be present in the hypothalamus. In addition, the efficacy of
Fig. 3 – Effect of intracerebroventricular treatment with NK1
receptor antagonist SR140333B on the increase in body
temperature induced by SP in captopril-treated rats. In A,
animals received captopril (5μg, i.c.v.), 30min before the
injection of SP (250, 500 and 750 ng) or saline (Sal). In B, animals
received an i.c.v. injection of SR140333B (SR, 3μg) or vehicle
(Veh, Tween800.3% in saline, 2μl) 30minbefore the samedose
of captopril . SP (500 ng) or saline (Sal) was given 30min after
captopril. Panel C summarizes the fever indexobserved in these
experiments. Values represent the means±S.E.M of the body
temperature (°C, panels A and B) or fever index (AUC in arbitrary
units, panel C) of 5–8 animals. *P<0.05 when compared to Sal
group. **P<0.05 when compared with Veh+SP-treated group.
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would suggest that this pyrogen raises central SP levels.
Thus, LPS may promptly mobilize SP and the participation
of the latter in fever induction by this agent appears to be
essential to the process since the blockade of the response by
the centrally administered NK1R antagonist SR140333B is
evident from the onset of the fever. LPS is a potent stimulus
for SP production and secretion both peripherally (Ng et al.,
2008; Wang et al., 2008) and also in the spinal cord (Bret-Dibat
et al., 1994). Thus, since SP increases body temperature in rats
and guinea pigs (Blatteis et al., 1994; Szelenyi et al., 1997), the
ability of LPS to trigger SP-mediated fever is not entirely
unexpected. On the other hand, the induction of fever only in
captopril-treated rats is somehow different from what was
reported previously. In fact, we actually observed that the
temperature variation among the animals injected with SP
alone was quite high in our experience with fever induction.
This raised the possibility that variations in SP metabolism
among the animals could trigger the observed temperature
variation. Angiotensin-converting enzyme (ACE) has been
reported to be among the enzymes that metabolize SP
(Skidgel and Erdos, 2004). Since the majority of ACE inhibitors,
including captopril, do not cross the blood–brain barrier we
decided to inject it directly into the brain. The treatment of
the animals with this drug allowed us to observe a more
consistent effect of SP in causing fever. However, it is also
known that bradykinin can induce fever (Coelho et al., 1997)
and, therefore, the febrile response observed after captopril
injection could be a result of an increase in bradykinin levels
due to ACE inhibition. However, this does not appear to be the
case, since the administration of the NK1R antagonist was
able to block the febrile response, suggesting that SP is, with its
metabolism blocked, the only substance responsible for the
observed fever.
It has been shown that systemic injection of LPS quite
rapidly enhances the expression of mRNA for IL-1β, IL-6 and
TNF-α in the mouse hypothalamus (Goujon et al., 1996; Pitossi
et al., 1997). Considering that IL-1β can facilitate the release
of SP from neurons (Morioka et al., 2002), we investigated
whether IL-1β-induced fever was mediated via SP production.
However, SR140333B, at a dose that reduces 85% of the LPS-
induced fever, did not alter the fever induced by IL-1β injected
i.c.v, suggesting that this cytokine does not cause fever via SP
release in the brain. Another possibility that should be
considered is that SP, once released after LPS injection,
induces the release of IL-1β which in turn causes fever.
Although to our knowledge there is no evidence that LPS can
directly bring about the release of SP in the CNS, there is
evidence supporting the possibility that SP acts on astrocytes
to release IL-1β (Martin et al., 1992). That would explain the
effectiveness of SR140333B against LPS-induced fever and not
in that induced by IL-1β; however, this hypothesis needs
further investigation.
IL-1β induces fever by a prostaglandin-dependent pathway
since it has been shown that the non-steroidal anti-inflam-
matory drug indomethacin inhibits the febrile response to this
cytokine (Hashimoto, 1991). In addition, it has been shown
that mice deficient in microsomal prostaglandin E synthase-1,
the final PGE2 synthesizing enzyme, do not develop fever after
IL-1β peripheral injection (Saha et al., 2005), although the
Fig. 4 – Effect of intracerebroventricular treatment with NK1 receptor antagonist SR140333B on fever induced by IL-1β and
CCL3/MIP-1α in rats. SR140333B (SR, 3 μg) or vehicle (Veh, Tween 80 0.3% in saline, 2 μl) was given i.c.v., 30 min before the
i.c.v. injection of IL-1β (3.12 ng, A and B) or CCL3/MIP-1α (500 pg, C andD) or saline (Sal). Values represent themeans±S.E.M of
the body temperature (°C, panels A and C) or fever index (AUC in arbitrary units, panels B and D) of 5–8 animals. *P<0.05 when
compared to corresponding value of Veh+Sal group.
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in the brain of these animals (Nilsberth et al., 2009b). However,
the febrile response is the result of a complex interplay
between various cytokines and particularly the fever induced
by LPS in rats is believed to involve prostaglandin-dependent
and -independent mechanisms (Fabricio et al., 2006; Nilsberth
et al., 2009a; Strijbos et al., 1992).
Since SP does not appear to mediate the IL-1β (and,
therefore, prostaglandin-dependent) febrile response we de-
cided to test the possible involvement of SP in the febrile
response induced by CCL3/MIP-1α. Although it has been
recently shown that CCL3/MIP-1α is not involved in LPS-
induced fever (Soares et al., 2009), this cytokine does induce
fever by a prostaglandin-independent pathway (Melo Soares
et al., 2006). Nevertheless, in the present study the NK1R
antagonist was not effective even in the prostaglandin-
independent fever generated by CCL-3/MIP-1α. We mentioned
before that different central mediators are involved in
different pathways for fever induction. We have shown that
endogenous opioids are not involved in the febrile response
induced by IL-1β (Fraga et al., 2008). However, endogenous
opioids induce fever independently of prostaglandinsynthesis and are important in the febrile response induced
by a CCL3/MIP-1α and ET-1 (mediators that also induce fever
by prostaglandin-independent pathways) (Fraga et al., 2008).
In a different way, we showed in this study that substance P
is not involved in both IL-1β- and CCL3/MIP-α-induced fever.
Therefore, the exact position of substance P in the fever
cascade remains to be elucidated, although it does not appear
to be downstream from IL-1β or CCL3/MIP-1α. In our opinion,
the definition of this neuropeptide's position in the network of
cytokines and mediators induced during the febrile response
comes before any speculation on how it could be activating
heat conservation/production mechanisms.
In summary, we showed here that a central, rather than a
peripheral action of SP through NK1R is relevant to LPS-
induced fever. However, this neuropeptide is not involved
in the febrile response triggered by IL-1β, which elicits a
prostaglandin-dependent fever, or CCL3/MIP-1α, which causes
a prostaglandin-independent fever. SP may participate in
the febrile response induced by other endogenous pyrogens
or it could be released before IL-1β or CCL3/MIP-1α; therefore,
the precise role of substance P in the febrile response to LPS
injection still needs further investigation.
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4.1. Animals
Experiments were conducted using maleWistar rats weighing
180±20 g, housed at 22±2 °C under a 12:12 h light–dark cycle
(lights on at 07:00) and with free access to rat chow and tap
water. All experiments were previously approved by the
institution's Ethics Committee for research on laboratory
animals and were performed in accordance with the guide-
lines for animal care and use set by the National Institutes of
Health (USA).
4.2. Temperature measurements
Abdominal body temperature was measured in conscious
unrestrained rats using data loggers (Subcue data loggers,
Calgary, Canada). These were implanted intraperitoneally
under ketamine–xylazine (60 mg/kg–7.5 mg/kg) anesthesia
and aseptic conditions 1 week prior to the experiment.
Animals were treated with oxytetracycline hydrochloride
(400 mg/kg i.m.) after surgery. Body temperature was contin-
uously monitored and recorded at 15-min intervals from 2 h
before any injection until 6 h after the injection of the
pyrogenic stimulus. For the fever index, the abdominal body
temperature from baseline (4 measurements preceding any
treatment) was determined for each individual animal and
the baseline value was subtracted from the individual data
points from 2 to 6 h after LPS, SP and CCL3/MIP-1α injection
and from 1 to 6 h after IL-1β injection, considering the start
time of the febrile response and excluding variations second-
ary to handling for injection. This approach allows calcula-
tion of the area under the curve (AUC) for each individual
animalwhichwas used as a fever index expressed in arbitrary
units. During the experiment, room temperature was kept at
24 °C.
4.3. Intracerebral cannula implantation
Whennecessary, under the same anesthesia described for the
implantation of the data loggers, a stainless steel guide
cannula (0.8 mm OD, 14 mm in length) was stereotaxically
inserted into the right lateral ventricle (Paxinos and Watson,
1998) and fixed to the skull with jeweler's screws embedded
in dental acrylic cement. All animals were then promptly
treated with oxytetracycline hydrochloride (400 mg/kg) and
the experiments were performed 1 week later. After each
experiment, the animal was anesthetized as before, and the
location of the cannula track was histologically verified.
Animals which showed cannula misplacement, blockage upon
injection or abnormal weight gain patterns were excluded from
the study.
4.4. Experimental protocols
A different group of rats was used for each experiment, i.e.,
each animal was used only once. In a first set of experiments,
rats were treated intraperitoneally (i.p.) with either the NK1
receptor antagonist SR140333B (0.3, 1 or 3 mg/kg dissolved insaline plus Tween 80 1%) or vehicle (2 ml/kg, control), 30 min
prior to injection of E. coli LPS (30 μg/kg, i.p.) or sterile saline
(2 ml/kg, i.p., control). To confirm the effectiveness of the
peripheral treatment, another group of animals was treated
with SR140333B (1 mg/kg) and after 30 min, under pentobar-
bital anesthesia (50 mg/kg, i.p.), they received an injection of
Evans Blue dye (50 mg/kg, i.v.) followed by 40 ng of SP (50 μl) or
the same volume of saline in the skin. After 15 min, animals
were killed, the dorsal skin was immediately excised and the
blue-stained area at each injection site was removed for dye
extraction (Rattmann et al., 2008). The plasma leakage was
measured as described previously (Brain and Williams, 1985).
In another set of experiments, rats were treated intracerebro-
ventricularly (i.c.v.) with either the NK1 receptor antagonist
SR140333B (0.3, 1 or 3 μg dissolved in 2 μl saline plus Tween
80 0.3%) or vehicle (2 μl, control), 30 min prior to injection of
E. coli LPS (30 μg/kg, i.p.) or sterile saline (2 ml/kg, i.p., control).
In the following set of experiments animals were treated with
SR140333B (3 μg/ 2 μl, i.c.v.) or the respective vehicle (Tween 80
0.3%) 30 min prior to injection of the angiotensin converting-
enzyme inhibitor captopril (5 μg/ 2 μl, i.c.v.) or the same
volume of vehicle (sterile saline), followed by the injection
of SP (250, 500 or 750 ng, i.c.v) or saline (2 μl) 30 min later. In
the final set of experiments, rats were treated with the same
dose of SR140333B or the vehicle 30 min before injecting either
IL-1β (3.1 ng/ 2 μl, i.c.v.) or CCL3/MIP-1α (500 pg) or sterile
saline. Pyrogenic stimuli were always injected between 10:00
and 11:00 h. Doses of each pyrogenic stimulus were based on
previous studies and do not represent doses that cause
maximal responses (Fraga et al., 2008; Melo Soares et al.,
2006; Werner et al., 2006; Zampronio et al., 2000).
4.5. Drugs
The following drugs were employed: LPS from E. coli 0111:B4,
substance P (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gli-Leu-Met-NH2)
and captopril (Sigma ChemCo., St. Louis, U.S.A.), rat IL-1β and rat
CCL3/MIP-1α (R&D Systems Inc., Minneapolis, U.S.A.), oxytetra-
cycline hydrochloride (Terramicina®, Pfizer, São Paulo, Brazil).
SR140333B ((S)1-{3-(3,4-dichloro-phenyl)-3-[2(4-phenyl-1-aza-
bicyclo[2.2.2]oct-1-yl]-ethyl]-piperidin-1-yl}-2-(3-isopropoxy-
phenyl)-ethanone benzenesulfonate) was a kind gift from
Sanofi-Aventis, France.
4.6. Statistical analysis
The results are presented as the mean±S.E.M. The statistical
significance among the groups was assessed using one-way
analysis of variance followed by Bonferroni's post-hoc test.
P values lower than 0.05 were considered an indication of
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